P-Cymene

P-Cymene

SCHEMBL4855141

Cc1cc(C)cc(S(=O)(=O)N[C@H](c2ccccc2)[C@H](N)c2ccccc2)c1.Cc1ccc(C(C)C)cc1.[Ru]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.45
ALDH1A1 P00352 2/20 0.45
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CNR2 P34972 1/20 0.39
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
KEAP1 Q14145 3/20 0.37
NFE2L2 Q16236 3/20 0.37
CA2 P00918 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
HPN P05981 2/20 0.36
PLAU P00749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Cymene SCHEMBL4857445 1.00 NPSR1 (0.45) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL2240125 0.91 ALDH1A1 (0.50) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL6743208 0.91 NPSR1 (0.47) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL3579869 0.91 ALDH1A1 (0.50) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL7527837 0.91 NPSR1 (0.47) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
Benzene SCHEMBL4859490 0.91 SLC1A3 (0.49) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL4864326 0.91 SLC1A3 (0.49) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL4862904 0.91 SLC1A3 (0.49) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
Benzene SCHEMBL4862827 0.91 SLC1A3 (0.49) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL6250944 0.90 SLC1A3 (0.50) NPSR1ALDH1A1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332622-B2 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGUKU KABUSHIKI KAISHA (JP) 2008-02-19 US disclosed
US-20050101787-A1 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGAKU KABUSHIKI KAISHA (JP) 2005-05-12 US disclosed
EP-1512678-A1 Process for preparing optically active nitro compounds and cyano compounds Kanto Kagaku Kabushiki Kaisha (JP) 2005-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101787-A1 Process for preparing optically active nitro compounds and cyano compounds NOS1, NOS2, NOX1 NPSR1 2609/4885ALDH1A1 1008/4885SLC1A3 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.